Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system

Cancer Immunology, Immunotherapy

Volumn 50, Issue 2, 2001, Pages 102-108

  Renner, Christoph ^d   Stehle, Ingo ^a   Lee, Fook Thean ^b   Hall, Cathrine ^b   Catimel, Bruno ^b   Nice, Edouard C ^b   Mountain, Angela ^b   Rigopoulos, Angela ^b   Brechbiel, Martin W ^c   Pfreundschuh, Michael ^a   Scott, Andrew M ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NONE

Author keywords

Bispecific antibodies; Hodgkin's lymphoma; Tumor targeting

Indexed keywords

BISPECIFIC ANTIBODY; CD16 ANTIBODY; CD30 ANTIBODY; IODINE 125; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG BINDING; DRUG DISTRIBUTION; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; FEMALE; HUMANS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; RECEPTORS, IGG; TISSUE DISTRIBUTION;

EID: 0035020908     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620100172     Document Type: Article

References (38)

1. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies
2. Bispecific antibody targeted T cell therapy of ovarian cancer: Clinical results and future directions
3. 2-NCA 102 monoclonal antibody: In vitro study of a specific agent for the detection of inflammatory loci
4. The cell of origin in Hodgkin's disease
5. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes
6. Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice
7. Production and use of anti-FcR bispecific antibodies
8. Bispecific monoclonal antibodies directed to CD16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones
9. A modeling analysis of monoclonal antibody perlocation the-rough tumors: A binding site barrier
10. Targeted cytotoxic cells in human peripheral blood lymphocytes
11. Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: The role of targeted T-cell co-stimulation via CD28
12. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody
13. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo
14. Preparation of iodine-125 labeled growth hormone of high specific radioactivity
15. Micropharmacology of monoclonal antibodies in solid tumors: Direct experimental evidence for a binding site barrier
16. Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy
17. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess
18. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
19. Instrumental biosensors: New perspectives for the analysis of biomolecular interactions
20. A rapid single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies
21. Comparative metabolism and retention of iodine-125, yittrium-90 and indium-111 radioimmunoconjugates by cancer cells
22. Tumor therapy by immune recruitment with bispecific antibodies
23. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells
24. The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies
25. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: The role of human T-cell subsets in a preclinical model
26. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody
27. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
28. Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody
29. Antibody-based immunological therapies
30. Targeting of anti-tumor responses with bispecific antibodies
31. Bispecific antibodies in cancer therapy
32. An unmodified anticarcinoma antibody, BR96, localizes to and inhibits the outgrowth of human tumors in nude mice
33. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts
34. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: A comparison of nine radiolabels
35. Hybrid antibody-mediated lysis of virus-infected cells
36. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu
37. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII
38. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA